Clinical Trial Update: Immunocompromised Swiss Cohorts Based Trial Platform [Phase 3]

View source ↗

Summary

Phase 3 trial update from a Swiss immunocompromised cohort platform has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunocompromised Patients

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Immunocompromised Patients | Phase 3 | Status: COMPLETED